Clinical trial
Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer
NCT00320515 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00320515 |
|---|---|
| Title | Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer |
| Official title | Phase 1/2 Study of Pemetrexed Plus Cisplatin in Unresectable, Advanced Gastric Carcinoma. |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasm, Gastric |
| Intervention type | Drug |
| Interventions | pemetrexed, cisplatin |
| Enrollment | 89 |
| Start date | Mar 1, 2004 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | May 3, 2006 |
| Last update posted | Sep 28, 2009 |
| Countries | Argentina, Mexico, South Korea, Taiwan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: